Completion of Nominated Adviser due diligence
Updated : 07:00
26 July 2022
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Completion of Nominated Adviser due diligence
Ondine Biomedical Inc. (AIM: OBI) announces that Strand Hanson Limited, appointed as the Company's Nominated Adviser on 27 April 2022, has confirmed completion of its due diligence.
Pursuant to Schedule 2(g)(ii) of the AIM Rules for Companies, the following disclosures are required:
Director | Current directorships |
Carolyn Cross | 12673011 Canada Inc. |
Nicolas Loebel | Advanced Photodynamic Technologies Inc. Axcess Medical Inc. Ondine Research Laboratories Ltd |
For more information, please visit: www.ondinebio.com or contact:
Ondine Biomedical Inc.
Carolyn Cross, CEO +001 (1) 604 669 0555
Strand Hanson Limited (Nominated and Financial Adviser)
Richard Johnson, James Harris, James Dance +44 (0) 20 7409 3494
Arden Partners plc (Broker)
Ruari McGirr +44 (0) 20 7614 5900
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard +44 (0) 77 1000 5910
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.